Viridian Therapeutics Inc Stock Price, News & Analysis

Viridian Therapeutics (NASDAQ: VRDN) reported Q3 2025 results and progress including an October 2025 BLA submission for veligrotug to the FDA with a Priority Review request and a potential U.S. launch in mid-2026 if approved. The company completed a comprehensive financing package in October providing up to $889 million of potential capital, including a $289.1 million equity offering, a royalty financing with DRI (up to $300 million, including $55 million upfront and $115 million near-term milestones) and an amended Hercules credit facility (up to $300 million).

Cash was approximately $887.9 million as of October 31, 2025. VRDN-003 pivotal trials (REVEAL-1/REVEAL-2) completed enrollment and topline readouts are expected in Q1 2026 and Q2 2026. VRDN-006 showed phase 1 IgG reduction proof-of-concept; VRDN-008 IND remains on track with healthy volunteer data expected in 2H 2026. Q3 R&D was $86.3M and G&A $24.3M.

Viridian Therapeutics (Nasdaq: VRDN) announced a successful late‑October 2025 submission of a Biologics License Application (BLA) to the U.S. FDA for veligrotug, an IV anti‑IGF‑1R monoclonal antibody for thyroid eye disease (TED).

The BLA is supported by two pivotal phase 3 trials, THRIVE and THRIVE‑2, which met all primary and secondary endpoints and showed rapid clinical benefit, including statistically significant diplopia response and resolution. Veligrotug has Breakthrough Therapy designation and Viridian requested Priority Review; FDA will decide on BLA acceptance within 60 days.

Viridian Therapeutics (NASDAQ: VRDN) priced an underwritten public offering of 11,425,000 shares of common stock at $22.00 per share, with a 30-day underwriter option for an additional 1,713,750 shares. Gross proceeds are expected to be approximately $251,350,000 before underwriting discounts, commissions and offering expenses. The offering is expected to close on or about October 23, 2025. Viridian intends to use proceeds, together with existing cash and short-term investments, to fund commercial launch activities for veligrotug and VRDN-003, plus R&D, working capital and general corporate purposes.

Jefferies, Leerink Partners, Evercore ISI and Stifel are joint book-running managers; Wedbush PacGrow is co-manager. A registration statement became effective on September 5, 2025.

Viridian Therapeutics (NASDAQ: VRDN) announced on October 21, 2025 that it commenced an underwritten public offering of shares of common stock and Series B non-voting convertible preferred stock. The company said all offered securities will be sold by Viridian and the underwriters have a 30-day option to purchase additional common shares.

Each Series B share will be convertible into 66.67 shares of common stock, subject to beneficial ownership conversion limits. Viridian intends to use proceeds, together with cash and short-term investments, to fund commercial launch activities for veligrotug and VRDN-003, R&D, working capital and general corporate purposes. A registration statement became effective on September 5, 2025. Jefferies, Leerink Partners, Evercore ISI and Stifel are joint book-runners; Wedbush PacGrow is co-manager.

Viridian Therapeutics (NASDAQ: VRDN) entered a royalty financing and amended credit facility to raise up to $300 million. The company received a $55 million upfront payment and may receive up to $115 million in near-term milestones tied to positive VRDN-003 REVEAL topline data and U.S. veligrotug approval. Proceeds plus existing cash are expected to fully fund commercial launches of veligrotug and VRDN-003. Viridian expects to submit the veligrotug BLA imminently and now projects VRDN-003 topline readouts in REVEAL-1 Q1 2026 and REVEAL-2 Q2 2026. An amended Hercules credit facility provides up to $300 million, including a required $50 million draw at closing.

Viridian Therapeutics (Nasdaq: VRDN) announced on October 2, 2025 that its Compensation Committee approved inducement grants of non-qualified stock options to purchase an aggregate of 147,650 shares to 4 new employees, with a Grant Date of October 1, 2025. The options were granted outside the company's 2016 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). Exercise price equals the closing price on the Grant Date. Vesting: 25% at one year, then monthly over 36 months, subject to continued employment.

Viridian Therapeutics (NASDAQ: VRDN) announced significant progress in its thyroid eye disease (TED) portfolio. The company has completed enrollment for both REVEAL-1 and REVEAL-2 phase 3 clinical trials for VRDN-003, exceeding target enrollment with 132 and 204 patients respectively. Topline data is expected in H1 2026.

Key developments include: USPTO granting composition patent for VRDN-003 until 2041, planned veligrotug BLA submission in November 2025 with potential mid-2026 launch under Priority Review, and positive VRDN-006 data showing consistent IgG reductions. The company's VRDN-008 IND submission remains on track for year-end 2025.

Viridian Therapeutics (Nasdaq: VRDN), a biopharmaceutical company focused on rare diseases, has granted non-qualified stock options to purchase 139,600 shares of common stock to 4 new employees as inducement awards. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months.

The company is currently advancing multiple clinical programs, including veligrotug (VRDN-001) and VRDN-003 for thyroid eye disease (TED), both reporting positive Phase 3 trial results. Additionally, Viridian is developing novel FcRn inhibitors (VRDN-006 and VRDN-008) for potential autoimmune disease treatments.

Viridian Therapeutics (Nasdaq: VRDN) reported significant progress in Q2 2025, highlighting key developments for its thyroid eye disease (TED) treatments. The company's lead drug candidate veligrotug received Breakthrough Therapy Designation in May 2025, with planned BLA submission in 2H 2025 and expected U.S. launch in 2026.

Key achievements include a $70 million upfront licensing deal with Kissei Pharmaceutical for Japan rights to veligrotug and VRDN-003, with potential additional milestones of $315 million plus royalties. The company reported strong durability data for veligrotug, with 70% of proptosis responders maintaining response at 52 weeks.

Financially, Viridian maintains a robust cash position of $563.4 million as of June 30, 2025, providing runway into 2H 2027. R&D expenses increased to $86.6 million in Q2 2025, up from $56.2 million year-over-year, reflecting expanded clinical trial activities.